On ECHEMI
Home > Drugs > Parkinson's disease dementia
Parkinson's disease dementia
Parkinson's disease is a slow-onset, selective disease that causes a series of extrapyramidal symptoms, with decreased movement, muscle rigidity, tremor and postural adjustment disorders as the main clinical manifestations. The disease is more common in middle-aged and elderly people, with the age of onset being mostly 55 to 61 years old, and the course of the disease is slowly progressive. It is significantly different from Alzheimer's disease.
  • Site of disease:

    Brain
  • Infectious :

    Not contagious
  • Frequent population:

    Parkinson's disease patients
  • Related symptoms:

    Myotonia tremorum, bradykinesia tremor tongue tremor hand tremor
Related Drugs
Dopamine Capsules
Indication: Used for Parkinson's disease and Parkinson's syndrome.
Manufacturer:

Guangzhou Hanfang Pharmaceutical Company Limited

Benztropine Hydrobromide Tablets
Indication: Used for Parkinson's disease, Parkinson's syndrome and drug-induced parkinsonism.
Amantadine Hydrochloride Capsules
Indication: It is used for Parkinson's disease, Parkinson's syndrome, drug-induced extrapyramidal disorders, Parkinson's syndrome after carbon monoxide poisoning, and Parkinson's syndrome in the elderly with cerebral arteriosclerosis. It is also used to prevent and treat respiratory infections caused by influenza A virus.
Manufacturer:

Yuanhe Pharmaceutical Group Industry Co., Ltd.

Carbidopa tablets
Indication: Used in combination with levodopa for Parkinson's disease and parkinson's syndrome.
Manufacturer:

Jinghua Pharmaceutical Group Co., Ltd.

Entacapone Tablets
Indication: This product can be used as an adjunct to the standard drugs levodopa/benserazide or levodopa/carbidopa to treat Parkinson's disease that cannot be controlled by the above drugs and end-of-dose phenomenon (symptom fluctuations).
Levodopa tablets
Indication: For Parkinson's disease and Parkinson's syndrome
Manufacturer:

Jilin Aodong--Taonan Pharnalentical Company Ltd

Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Manufacturer:

Jilin Aodong--Taonan Pharnalentical Company Ltd

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.